The primary objective of this proposal is to provide a more precise characterization of the factors that predict pulmonary fibrosis (PF) development and progression in specific populations with the goal of defining groups that might benefit from participation in early PF screening studies. Idiopathic pulmonary fibrosis (IPF), the most common and severe form of pulmonary fibrosis (PF) has a mortality rate comparable to that of many end- stage malignancies Although IPF has historically been unresponsive to pharmacotherapy, recent studies have demonstrated that medical therapy can reduce the rate of decline in lung function, particularly when started early in the course of disease. Our recent findings demonstrated that early disease detection for PF is an achievable goal. In 1st degree relatives of patients with PF we have demonstrated ILA in 38% of those we have evaluated, and 33% of those with ILA were found to have signs of more advanced disease. These relatives have been referred for clinical evaluations, some of whom have begun on anti-fibrotic therapy for IPF/familial PF. While these findings demonstrate that a landmark shift from reacting - to preventing ? PF progression in close relatives is possible, it is not known the extent to which early PF can be detected in other unique populations at risk. Based on these findings we hypothesize that measurable characteristics can be identified in 1) smokers with and without COPD, 2) in patients with early stage lung cancer, and 3) in those with prior imaging abnormalities, that will help to distinguish those who already have PF (and those with the greatest risk to progress from early stages of PF) from those unlikely to develop this disease. The results of these studies will improve our understanding of early disease detection for PF, as well as setting the stage for trials aimed at the recruiting these specific populations for early institution of novel and existing medical therapies.

Public Health Relevance

Idiopathic pulmonary fibrosis, a disorder characterized by lung scarring that has a prognosis worse than that of most cancers, can be slowed with medications targeting fibrosis but it is frequently identified in advanced stages. Our work suggests that early stages of pulmonary fibrosis can be detected in screening studies in first-degree relatives of patients with pulmonary fibrosis. This proposal is designed to provide a more precise characterization of the factors that predict pulmonary fibrosis development and progression in additional populations with the goal of defining groups that might benefit from participation in early screening studies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL111024-07
Application #
9890852
Study Section
Respiratory Integrative Biology and Translational Research Study Section (RIBT)
Program Officer
Gan, Weiniu
Project Start
2013-07-01
Project End
2023-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Ash, Samuel Y; Harmouche, Rola; Putman, Rachel K et al. (2018) Association between acute respiratory disease events and the MUC5B promoter polymorphism in smokers. Thorax 73:1071-1074
Axelsson, Gisli Thor; Putman, Rachel K; Araki, Tetsuro et al. (2018) Interstitial lung abnormalities and self-reported health and functional status. Thorax 73:884-886
Ash, Samuel Y; Harmouche, Rola; Ross, James C et al. (2018) Interstitial Features at Chest CT Enhance the Deleterious Effects of Emphysema in the COPDGene Cohort. Radiology 288:600-609
Diaz, Alejandro A; Strand, Matthew; Coxson, Harvey O et al. (2018) Disease Severity Dependence of the Longitudinal Association Between CT Lung Density and Lung Function in Smokers. Chest 153:638-645
Miller, Ezra R; Putman, Rachel K; Vivero, Marina et al. (2018) Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. Am J Respir Crit Care Med 197:955-958
Rosas, Ivan O; Goldberg, Hilary J; Collard, Harold R et al. (2018) A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest 153:94-104
Putman, Rachel K; Gudmundsson, Gunnar; Araki, Tetsuro et al. (2017) The MUC5B promoter polymorphism is associated with specific interstitial lung abnormality subtypes. Eur Respir J 50:
Ash, Samuel Y; Harmouche, Rola; Putman, Rachel K et al. (2017) Clinical and Genetic Associations of Objectively Identified Interstitial Changes in Smokers. Chest 152:780-791
Ash, Samuel Y; Harmouche, Rola; Ross, James C et al. (2017) The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers. Acad Radiol 24:941-946
Miller, Ezra R; Hunninghake, Gary M (2017) Malaria and the development of pulmonary fibrosis. Eur Respir J 50:

Showing the most recent 10 out of 40 publications